D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.

dc.contributor.author

Pruszynski, Marek

dc.contributor.author

Koumarianou, Eftychia

dc.contributor.author

Vaidyanathan, Ganesan

dc.contributor.author

Chitneni, Satish

dc.contributor.author

Zalutsky, Michael R

dc.coverage.spatial

United States

dc.date.accessioned

2015-10-07T17:19:24Z

dc.date.issued

2015-01

dc.description.abstract

INTRODUCTION: Proteins that undergo receptor-mediated endocytosis are subject to lysosomal degradation, requiring radioiodination methods that minimize loss of radioactivity from tumor cells after this process occurs. To accomplish this, we developed the residualizing radioiodination agent N(ϵ)-(3-[()I]iodobenzoyl)-Lys(5)-N(α)-maleimido-Gly(1)-D-GEEEK (Mal-D-GEEEK-[()I]IB), which enhanced tumor uptake but also increased kidney activity and necessitates generation of sulfhydryl moieties on the protein. The purpose of the current study was to synthesize and evaluate a new D-amino acid based agent that might avoid these potential problems. METHODS: N(α)-(3-iodobenzoyl)-(5-succinimidyloxycarbonyl)-D-EEEG (NHS-IB-D-EEEG), which contains 3 D-glutamates to provide negative charge and a N-hydroxysuccinimide function to permit conjugation to unmodified proteins, and the corresponding tin precursor were produced by solid phase peptide synthesis and subsequent conjugation with appropriate reagents. Radioiodination of the anti-HER2 antibody trastuzumab using NHS-IB-D-EEEG and Mal-D-GEEEK-IB was compared. Paired-label internalization assays on BT474 breast carcinoma cells and biodistribution studies in athymic mice bearing BT474M1 xenografts were performed to evaluate the two radioiodinated D-peptide trastuzumab conjugates. RESULTS: NHS-[(131)I]IB-D-EEEG was produced in 53.8%±13.4% and conjugated to trastuzumab in 39.5%±7.6% yield. Paired-label internalization assays with trastuzumab-NHS-[(131)I]IB-D-EEEG and trastuzumab-Mal-D-GEEEK-[(125)I]IB demonstrated similar intracellular trapping for both conjugates at 1h ((131)I, 84.4%±6.1%; (125)I, 88.6%±5.2%) through 24h ((131)I, 60.7%±6.8%; (125)I, 64.9%±6.9%). In the biodistribution experiment, tumor uptake peaked at 48 h (trastuzumab-NHS-[(131)I]IB-D-EEEG, 29.8%±3.6%ID/g; trastuzumab-Mal-D-GEEEK-[(125)I]IB, 45.3%±5.3%ID/g) and was significantly higher for (125)I at all time points. In general, normal tissue levels were lower for trastuzumab-NHS-[(131)I]IB-D-EEEG, with the differences being greatest in kidneys ((131)I, 2.2%±0.4%ID/g; (125)I, 16.9%±2.8%ID/g at 144 h). CONCLUSION: NHS-[(131)I]IB-D-EEEG warrants further evaluation as a residualizing radioiodination agent for labeling internalizing antibodies/fragments, particularly for applications where excessive renal accumulation could be problematic.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/25240914

dc.identifier

S0969-8051(14)00482-X

dc.identifier.eissn

1872-9614

dc.identifier.uri

https://hdl.handle.net/10161/10679

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Nucl Med Biol

dc.relation.isversionof

10.1016/j.nucmedbio.2014.08.007

dc.subject

Radioiodination

dc.subject

Radionuclide therapy

dc.subject

Residualizing agents

dc.subject

Trastuzumab

dc.subject

d-amino acid peptide

dc.subject

Animals

dc.subject

Antibodies, Monoclonal, Humanized

dc.subject

Biological Transport

dc.subject

Cell Line, Tumor

dc.subject

Esters

dc.subject

Female

dc.subject

Humans

dc.subject

Iodine Radioisotopes

dc.subject

Isotope Labeling

dc.subject

Mice

dc.subject

Oligopeptides

dc.subject

Radiochemistry

dc.subject

Trastuzumab

dc.title

D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodination.

dc.type

Journal article

duke.contributor.orcid

Vaidyanathan, Ganesan|0000-0003-3041-8275

duke.contributor.orcid

Chitneni, Satish|0000-0003-1183-2286

duke.contributor.orcid

Zalutsky, Michael R|0000-0002-5456-0324

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/25240914

pubs.begin-page

19

pubs.end-page

27

pubs.issue

1

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Pathology

pubs.organisational-group

Radiation Oncology

pubs.organisational-group

Radiology

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

42

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S096980511400482X-main.pdf
Size:
673.18 KB
Format:
Adobe Portable Document Format
Description:
Published version